Alector (ALEC) vs X4 Pharmaceuticals (XFOR)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Alector (ALEC) has outperformed X4 Pharmaceuticals (XFOR) over the past year, gaining 88.3% versus a loss of 20.0%. Over five years, ALEC leads with a -88.3% price change compared with -97.8% for XFOR. Alector is the larger company by market cap ($347.6 million vs $306.3 million), about 1.1 times the size, while X4 Pharmaceuticals is growing revenue faster (+150.0% vs -79.1%).
On valuation, X4 Pharmaceuticals trades at a lower trailing P/E (5.5x vs 6.3x for Alector). Alector converts more of its revenue into profit, with a net margin of -679.2% versus -1218.4%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ALEC | XFOR |
|---|---|---|
| Share price | $2.34 | $3.00 |
| Market cap | $347.63M | $306.34M |
| 1-day change | +1.52% | +1.35% |
| YTD return | +49.68% | -25.00% |
| 1-year return | +88.31% | -20.00% |
| 5-year return | -88.28% | -97.79% |
| P/E ratio (TTM) | 6.31 | 5.45 |
| EPS (TTM) | $0.37 | $0.55 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $21.05M | $6.50M |
| Revenue growth (YoY) | -79.07% | +150.00% |
| Net income (latest FY) | $-142.93M | $-79.20M |
| Gross margin | — | 11.43% |
| Operating margin | -741.30% | -1336.66% |
| Net margin | -679.16% | -1218.45% |
| 52-week high | $2.84 | $4.83 |
| 52-week low | $1.09 | $2.43 |
| Distance from 52-week high | -17.78% | -37.89% |
| Analyst consensus | buy | strong_buy |
| Avg. price target upside | +89.29% | +286.67% |
| Average volume | 3.34M | 877.70K |
| Shares outstanding | 148.88M | 102.11M |
| Employees | 103 | 45 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ALEC has outperformed XFOR by 108.3 percentage points over the past year.
- Alector is more profitable, keeping -679.2 cents of every revenue dollar as net income versus -1218.4 cents for X4 Pharmaceuticals.
- X4 Pharmaceuticals grew revenue faster in its latest fiscal year (+150.00% vs -79.07%).
About Alector
ALEC stock →Alector, Inc., a clinical stage biotechnology company, develops therapies to counteract the progression of neurodegeneration in the United States. Its pipeline includes Nivisnebart, an investigational human recombinant monoclonal antibody for treating prevalent neurodegenerative diseases; AL137, an anti-amyloid beta antibody paired in preclinical development for the potential treatment of Alzheimer's disease; and AL050, a GCase enzyme replacement therapy in preclinical development for the potential treatment of Parkinson's disease and Lewy body dementia in patients having GBA1 gene mutations.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 103 employees
About X4 Pharmaceuticals
XFOR stock →X4 Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases of the immune system. It offers XOLREMDI, an orally small-molecule selective antagonist of chemokine receptor CXCR4, which is in phase 3 clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 45 employees
ALEC vs XFOR FAQ
Which is bigger, Alector or X4 Pharmaceuticals?
Alector (ALEC) is larger, with a market capitalization of $347.63M compared with $306.34M for X4 Pharmaceuticals (XFOR).
Which stock has performed better over the past year, ALEC or XFOR?
ALEC returned +88.31% over the past 12 months, compared with -20.00% for XFOR (price return, excluding dividends). Past performance does not predict future results.
Which has the lower P/E ratio, ALEC or XFOR?
XFOR has the lower trailing P/E at 5.5, versus 6.3 for ALEC. A lower P/E is not by itself a sign of a better investment; it can reflect slower expected growth or higher risk.
Are Alector and X4 Pharmaceuticals in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.